Want to see GNLX full AI Analyst Report?
Top Page
Genelux Corp.
(NASDAQ:GNLX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.50
▼(-8.09% Downside)
Action:Reiterated
Date:08/29/26
The score is primarily constrained by weak financial performance driven by near-zero revenue, large ongoing losses, and significant cash burn that implies continued reliance on external financing. Technicals are mixed, with the stock trading below major moving averages despite neutral RSI and only modestly negative MACD. Valuation is also constrained because the negative P/E reflects unprofitability and dividend support is not indicated.
Positive Factors
Modest Leverage
Relatively low leverage gives Genelux more financial flexibility than a heavily indebted biotech and limits interest-related pressure. This provides some balance-sheet support while the company funds clinical development, although continued losses could still increase financing needs.
Negative Factors
Near-Zero Revenue and Large Losses
Genelux has no established commercial revenue base to offset research and development costs, leaving financial performance dependent on future clinical and regulatory success. The scale of current losses indicates that meaningful operating profitability is unlikely without a successful product or partnership.
Read all positive and negative factors
Positive Factors
Negative Factors
Modest Leverage
Relatively low leverage gives Genelux more financial flexibility than a heavily indebted biotech and limits interest-related pressure. This provides some balance-sheet support while the company funds clinical development, although continued losses could still increase financing needs.
Read all positive factors
Genelux Corp. (GNLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$120.35M
Dividend YieldN/A
Average Volume (3M)156.94K
Price to Earnings (P/E)―
Beta (1Y)0.81
Revenue GrowthN/A
EPS Growth-1.31%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.89
Shares Outstanding45,245,335
10 Day Avg. Volume178,540
30 Day Avg. Volume156,945
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)14.04
Price to Sales (P/S)20261.21
P/FCF Ratio-6.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.67Price Target Upside623.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Genelux Corp. Business Overview & Revenue Model
Company Description
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi...
How the Company Makes Money
As a clinical-stage biotechnology company, Genelux does not have widely disclosed, established product sales as a primary revenue source; commercial revenue from approved therapeutics is null. The company’s funding has historically been driven pri...
Genelux Corp. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.00K | 8.00K | 8.00K | 170.00K | 11.07M | 0.00 |
| Gross Profit | -141.00K | -566.00K | -895.00K | -848.00K | 10.10M | -895.00K |
| EBITDA | -34.19M | -31.57M | -28.97M | -26.46M | -1.73M | -13.67M |
| Net Income | -33.79M | -32.15M | -29.87M | -28.30M | -5.21M | -17.80M |
Balance Sheet | ||||||
| Total Assets | 26.20M | 19.03M | 34.72M | 27.89M | 5.53M | 8.13M |
| Cash, Cash Equivalents and Short-Term Investments | 18.67M | 14.60M | 30.89M | 23.19M | 397.00K | 4.50M |
| Total Debt | 2.42M | 1.69M | 1.87M | 2.52M | 26.35M | 25.31M |
| Total Liabilities | 10.09M | 7.48M | 8.44M | 8.42M | 41.31M | 41.24M |
| Stockholders Equity | 16.11M | 11.54M | 26.27M | 19.47M | -35.78M | -33.11M |
Cash Flow | ||||||
| Free Cash Flow | -28.68M | -26.37M | -21.61M | -21.30M | -3.62M | -6.58M |
| Operating Cash Flow | -25.28M | -25.27M | -21.23M | -20.27M | -3.57M | -6.58M |
| Investing Cash Flow | 8.71M | 12.14M | -8.13M | -14.72M | -49.00K | 0.00 |
| Financing Cash Flow | 19.20M | 9.89M | 28.51M | 44.02M | -478.00K | -270.00K |
Genelux Corp. Risk Analysis
Genelux Corp. disclosed 88 risk factors in its most recent earnings report. Genelux Corp. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Genelux Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $1.63B | -16.77 | -94.82% | ― | ― | 35.82% | |
54 Neutral | $233.08M | -1.03 | -68.99% | ― | 196.02% | 98.71% | |
53 Neutral | $211.01M | -1.68 | -87.05% | ― | ― | -29.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $291.16M | -2.31 | -65.08% | ― | -23.36% | 27.52% | |
46 Neutral | $217.85M | -1.38 | -181.73% | ― | -64.32% | 25.83% | |
45 Neutral | $120.35M | -2.99 | -195.42% | ― | ― | -1.31% |
* Healthcare Sector Average
GNLX
Genelux Corp.
2.66
-0.71
-21.07%
CHRS
Coherus Biosciences
1.41
0.22
18.49%
FATE
Fate Therapeutics
2.43
1.40
135.92%
TNXP
Tonix Pharma
13.59
-14.07
-50.87%
CRBP
Corbus Pharmaceuticals
10.91
1.17
12.01%
FBRX
Forte Biosciences
76.99
65.94
596.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.